Anticoagulation inhibits tumor cell-mediated release of platelet angiogenic proteins and diminishes platelet angiogenic response

Blood

Volumn 123, Issue 1, 2014, Pages 101-112

  Battinelli, Elisabeth M ^a,b   Markens, Beth A ^a,b   Kulenthirarajan, Rajesh A ^a,b   Machlus, Kellie R ^a,b   Flaumenhaft, Robert ^c   Italiano Jr , Joseph E ^a,b,d  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^d BOSTON CHILDREN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE DIPHOSPHATE; ANGIOGENIC PROTEIN; ANTICOAGULANT AGENT; DALTEPARIN; FONDAPARINUX; HEPARIN; PROTEINASE ACTIVATED RECEPTOR 1; REGULATOR PROTEIN; THROMBIN; VASCULOTROPIN; ANTITHROMBOCYTIC AGENT; POLYSACCHARIDE; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ANGIOGENESIS; ANTIANGIOGENIC ACTIVITY; ANTICOAGULANT THERAPY; ARTICLE; CANCER SURVIVAL; HUMAN; HUMAN CELL; IN VIVO STUDY; MCF 7 CELL LINE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN SECRETION; SIGNAL TRANSDUCTION; THROMBOCYTE; UMBILICAL VEIN ENDOTHELIAL CELL; BLOOD CLOTTING; CELL STRAIN MCF 7; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; FLUORESCENCE MICROSCOPY; METABOLISM; NEOVASCULARIZATION (PATHOLOGY);

ANGIOGENIC PROTEINS; ANTICOAGULANTS; BLOOD COAGULATION; BLOOD PLATELETS; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; MCF-7 CELLS; MICROSCOPY, FLUORESCENCE; NEOVASCULARIZATION, PATHOLOGIC; PLATELET AGGREGATION INHIBITORS; POLYSACCHARIDES; RECEPTOR, PAR-1; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84894412680     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-02-485011     Document Type: Article

References (50)

1. Leslie M. Cell biology. Beyond clotting: the powers of platelets. Science. 2010; 328(5978): 562-564.
2. Suppiah R, Shaheen PE, Elson P, et al Thrombocytosis as a prognostic factor for survival in patients with metastatic renal cell carcinoma. Cancer. 2006; 107(8): 1793-1800. (Pubitemid 44582948)
3. Scholz HS, Petru E, Gücer F, Haas J., Tamussino K, Winter R. Preoperative thrombocytosis is an independent prognostic factor in stage III and IV endometrial cancer. Anticancer Res. 2000; 20(5C): 3983-3985. (Pubitemid 32002309)
4. Kandemir EG, Mayadagli A, Karagoz B., Bilgi O, Turken O, Yaylaci M. Prognostic significance of thrombocytosis in node-negative colon cancer. J Int Med Res. 2005; 33(2): 228-235. (Pubitemid 40372439)
5. Taucher S, Salat A, Gnant M., et al.; Austrian Breast and Colorectal Cancer Study Group. Impact of pretreatment thrombocytosis on survival in primary breast cancer. Thromb Haemost. 2003; 89(6): 1098-1106. (Pubitemid 36798163)
6. Gasic GJ, Gasic TB, Stewart CC Antimetastatic effects associated with platelet reduction. Proc Natl Acad Sci USA. 1968; 61(1): 46-52.
7. Karpatkin S, Pearlstein E. Role of platelets in tumor cell metastases. Ann Intern Med. 1981; 95(5): 636-641. (Pubitemid 12231807)
8. Camerer E, Qazi AA, Duong D.N., Cornelissen I., Advincula R, Coughlin SR Platelets, protease-activated receptors, and fibrinogen in hematogenous metastasis. Blood. 2004; 104(2): 397-401. (Pubitemid 38900020)
9. Demers M, Ho-Tin-Noé B, Schatzberg D, Yang JJ, Wagner DD. Increased efficacy of breast cancer chemotherapy in thrombocytopenic mice. Cancer Res. 2011; 71(5): 1540-1549.
10. Battinelli EM, Markens BA, Italiano JE Jr. Release of angiogenesis regulatory proteins from platelet alpha granules: modulation of physiologic and pathologic angiogenesis. Blood. 2011; 118(5): 1359-1369.
11. Sabrkhany S, Griffioen AW, Oude Egbrink MG. The role of blood platelets in tumor angiogenesis. Biochim Biophys Acta. 2011; 1815(2): 189-196.
12. Italiano JE J.r., Richardson JL, Patel-Hett S, et al Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released. Blood. 2008; 111(3): 1227-1233. (Pubitemid 351213404)
13. Gisterek I, Matkowski R, Lacko A., et al Serum vascular endothelial growth factors a, C and d in human breast tumors. Pathol Oncol Res. 2010; 16(3): 337-344.
14. Erpenbeck L, Schön MP. Deadly allies: the fatal interplay between platelets and metastasizing cancer cells. Blood. 2010; 115(17): 3427-3436.
15. Rickles FR, Falanga A. Molecular basis for the relationship between thrombosis and cancer. Thromb Res. 2001; 102(6):V215-V224. (Pubitemid 32539212)
16. Gay LJ, Felding-Habermann B. Contribution of platelets to tumour metastasis. Nat Rev Cancer. 2011; 11(2): 123-134.
17. Bambace NM, Holmes CE The platelet contribution to cancer progression. J Thromb Haemost. 2011; 9(2): 237-249.
18. Gasic GJ. Role of plasma, platelets, and endothelial cells in tumor metastasis. Cancer Metastasis Rev. 1984; 3(2): 99-114.
19. Bastida E, Escolar G, Almirall L., Ordinas A. Platelet activation induced by a human neuroblastoma tumor cell line is reduced by prior administration of ticlopidine. Thromb Haemost. 1986; 55(3): 333-337. (Pubitemid 16074158)
20. Heinmöller E., Schropp T, Kisker O., Simon B, Seitz R, Weinel RJ Tumor cell-induced platelet aggregation in vitro by human pancreatic cancer cell lines. Scand J Gastroenterol. 1995; 30(10): 1008-1016.
21. Boukerche H, Berthier-Vergnes O, Penin F., et al Human melanoma cell lines differ in their capacity to release ADP and aggregate platelets. Br J Haematol. 1994; 87(4): 763-772. (Pubitemid 24264649)
22. Jurasz P, Chung AW, Radomski A, Radomski MW Nonremodeling properties of matrix metalloproteinases: the platelet connection. Circ Res. 2002; 90(10): 1041-1043. (Pubitemid 34627901)
23. Nijziel MR, van Oerle R, Hillen HF, Hamulyák K. From Trousseau to angiogenesis: the link between the haemostatic system and cancer. Neth J Med. 2006; 64(11): 403-410. (Pubitemid 46001908)
24. Klerk CP, Smorenburg SM, Otten H.M., et al The effect of low molecular weight heparin on survival in patients with advanced malignancy. J Clin Oncol. 2005; 23(10): 2130-2135. (Pubitemid 46218704)
25. Kakkar AK, Levine MN, Kadziola Z, et al Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS). J Clin Oncol. 2004; 22(10): 1944-1948. (Pubitemid 41095187)
26. Lee AY, Rickles FR, Julian J.A., et al Randomized comparison of low molecular weight heparin and coumarin derivatives on the survival of patients with cancer and venous thromboembolism. J Clin Oncol. 2005; 23(10): 2123-2129. (Pubitemid 46218703)
27. Nagy Z, Turcsik V, Blaskó G. The effect of LMWH (Nadroparin) on tumor progression. Pathol Oncol Res. 2009; 15(4): 689-692.
28. Khosravi Shahi P., Soria Lovelle A, Pérez Manga G. Tumoral angiogenesis and breast cancer. Clin Transl Oncol. 2009; 11(3): 138-142.
29. Bobek V, Boubelik M, Kovarík J, Taltynov O. Inhibition of adhesion breast cancer cells by anticoagulant drugs and cimetidine. Neoplasma. 2003; 50(2): 148-151. (Pubitemid 36560051)
30. Vlodavsky I, Mohsen M, Lider O., et al Inhibition of tumor metastasis by heparanase inhibiting species of heparin. Invasion Metastasis. 1994-1995; 14(1-6): 290-302.
31. Sciumbata T, Caretto P, Pirovano P., et al Treatment with modified heparins inhibits experimental metastasis formation and leads, in some animals, to long-term survival. Invasion Metastasis. 1996; 16(3): 132-143. (Pubitemid 27239184)
32. Lee AE, Rogers LA, Longcroft J.M., Jeffery RE Reduction of metastasis in a murine mammary tumour model by heparin and polyinosinic-polycytidylic acid. Clin Exp Metastasis. 1990; 8(2): 165-171. (Pubitemid 20158244)
33. Ludwig RJ, Boehme B, Podda M., et al Endothelial P-selectin as a target of heparin action in experimental melanoma lung metastasis. Cancer Res. 2004; 64(8): 2743-2750. (Pubitemid 38500611)
34. Lapierre F, Holme K, Lam L., et al Chemical modifications of heparin that diminish its anticoagulant but preserve its heparanase-inhibitory, angiostatic, anti-tumor and anti-metastatic properties. Glycobiology. 1996; 6(3): 355-366. (Pubitemid 26160105)
35. Engelberg H. Actions of heparin that may affect the malignant process. Cancer. 1999; 85(2): 257-272. (Pubitemid 29051278)
36. Khorana AA, Sahni A, Altland O.D., Francis CW Heparin inhibition of endothelial cell proliferation and organization is dependent on molecular weight. Arterioscler Thromb Vasc Biol. 2003; 23(11): 2110-2115. (Pubitemid 37433208)
37. Norrby K. Low-molecular-weight heparins and angiogenesis. APMIS. 2006; 114(2): 79-102. (Pubitemid 43356919)
38. Pepe G, Giusti B, Attanasio M., et al Tissue factor and plasminogen activator inhibitor type 2 expression in human stimulated monocytes is inhibited by heparin. Semin Thromb Hemost. 1997; 23(2): 135-141. (Pubitemid 27276099)
39. Nierodzik ML, Karpatkin S. Thrombin induces tumor growth, metastasis, and angiogenesis: evidence for a thrombin-regulated dormant tumor phenotype. Cancer Cell. 2006; 10(5): 355-362. (Pubitemid 44693468)
40. Möhle R., Green D, Moore M.A., Nachman RL, Rafii S. Constitutive production and thrombin-induced release of vascular endothelial growth factor by human megakaryocytes and platelets. Proc Natl Acad Sci USA. 1997; 94(2): 663-668. (Pubitemid 27053690)
41. Li JJ, Huang YQ, Basch R, Karpatkin S. Thrombin induces the release of angiopoietin-1 from platelets. Thromb Haemost. 2001; 85(2): 204-206. (Pubitemid 32140561)
42. Jiang L, Xu C, Yu S., et al A critical role of thrombin/PAR-1 in ADP-induced platelet secretion and the second wave of aggregation. J Thromb Haemost. 2013; 11(5): 930-940.
43. Ma L, Perini R, McKnight W., et al Proteinase-activated receptors 1 and 4 counter-regulate endostatin and VEGF release from human platelets. Proc Natl Acad Sci USA. 2005; 102(1): 216-220. (Pubitemid 40094455)
44. Italiano JE J.r., Lecine P, Shivdasani R.A., Hartwig JH Blood platelets are assembled principally at the ends of proplatelet processes produced by differentiated megakaryocytes. J Cell Biol. 1999; 147(6): 1299-1312. (Pubitemid 30012814)
45. Bambace NM, Levis JE, Holmes CE The effect of P2Y-mediated platelet activation on the release of VEGF and endostatin from platelets. Platelets. 2010; 21(2): 85-93.
46. Marchetti M, Diani E, ten Cate H, Falanga A. Characterization of the thrombin generation potential of leukemic and solid tumor cells by calibrated automated thrombography. Haematologica. 2012; 97(8): 1173-1180.
47. Jonnalagadda D, Izu LT, Whiteheart SW Platelet secretion is kinetically heterogeneous in an agonist-responsive manner. Blood. 2012; 120(26): 5209-5216.
48. Eslam RB, Reiter N, Kaider A., Eichinger S, Lang IM, Panzer S. Regulation of PAR-1 in patients undergoing percutaneous coronary intervention: effects of unfractionated heparin and bivalirudin. Eur Heart J. 2009; 30(15): 1831-1836.
49. Borsig L. Heparin as an inhibitor of cancer progression. Prog Mol Biol Transl Sci. 2010; 93: 335-349.
50. Reiter R, Derhaschnig U, Spiel A., et al Regulation of protease-activated receptor 1 (PAR1) on platelets and responsiveness to thrombin receptor activating peptide (TRAP) during systemic inflammation in humans. Thromb Haemost. 2003; 90(5): 898-903. (Pubitemid 37427860)